阿伐他汀对急性冠状动脉综合征患者NF-κB和可溶性细胞间黏附因子-1的影响

Effect of atorvastatin on the nuclear factor-κB and soluble inter-cellular adhesion molecules-1 in patients with acute coronary syndrome

目的 :探讨阿伐他汀对急性冠状动脉综合征 (ACS)患者治疗后核因子 κBp6 5 (NF κBp6 5 )阳性率和可溶性细胞间黏附因子 1(sICAM 1)浓度的影响及其临床意义。方法 :6 8例ACS患者随机分成阿伐他汀治疗组(阿伐他汀组 ,37例 )及常规治疗组 (常规组 ,31例 ) ,治疗前及治疗 12周后采用夹心酶联免疫吸附法 (ELISA法 )测定血浆sICAM 1浓度和免疫组织化学染色法测定外周血单核细胞NF κBp6 5阳性率 ,比较两者的变化。结果 :治疗前两组比较NF κBp6 5阳性率和sICAM 1浓度水平差异无显著性 (P >0 .0 5 ) ;治疗 12周后 ,常规治疗组NF κBp6 5阳性率和sICAM 1浓度水平前后差异无显著性 (P >0 .0 5 ) ;而阿伐他汀组NF κBp6 5阳性率和sICAM 1浓度水平治疗后明显低于治疗前 (P <0 .0 5 )。结论 :阿伐他汀对ACS患者有抗炎和稳定粥样斑块作用 ,其作用可能与降低NF κB活性和sICAM

Objective To determine the effect of atorvastatin on the activity of peripheral blood lymocyte nuclear factor-κB (NF-κB) and plasma soluble inter-cellular adhesion molecules-1 (sICAM-1) in acute coronary syndromes. Methods Sixty-eight patients with acute coronary syndrome were randomly divided into atorvastatin therapeutic group (n=37) and conventional therapeutic group (n=31). Enzyme-linked immunosorbent assay was used to measure the plasma sICAM-1, and immunohistochemical method was used to measure the activity of NF-κB in the peripheral blood lymphocyte before and 12 weeks after the therapy in the two groups. Results Before the therapy, the level of NF-κB activity in the peripheral blood lymphocytes [(45.2±8.4)% vs (40.8±9.2)%,P>0.05] and the plasma sICAM-1 [(357.2±84.5) ng/ml vs (365.5±91.3) ng/ml, P>0.05] in the two groups had no significant difference. After 12 weeks of the therapy, in the conventional group the level of NF-κB activity in the peripheral blood lymphocytes [(40.8±9.2)% vs (38.7±8.9)%,P>0.05]and the plasma sICAM-1 [(357.2±84.5) ng/ml vs (365.5±91.3) ng/ml, P>0.05] still had no significant difference. But in the atorvastatin group the level of NF-κB activity in the peripheral blood lymphocyte [(45.2±8.4)% vs (25.6±7.9)%,P<0.05 and the plasma soluble inter-cellular adhesion molecule-1 [(357.2±84.5) ng/ml vs (175.8±75.6) ng/ml, P<0.05] did show a significant difference.Conclusion The cholesterol-lowering therapy with atorvastatin can reduce the inflammation and stabilize the plaque in the acute coronary syndrome, which may be related to the inhibition of NF-κB and sICAM-1 activities.